Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 5, 2014

Primary Completion Date

December 24, 2014

Study Completion Date

December 24, 2014

Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
DRUG

Eltrombopag

White to off white bi-convex round tablets containing eltrombopag 50 mg for oral administration

DRUG

Cyclosporine

Soft gelatine capsule containing cyclosporine 100 mg for oral administration. Cyclosporine will be administered at the doses of 200 mg (2 x 100 mg capsules) or 600 mg (6 x 100 mg capsules)

Trial Locations (1)

66211

GSK Investigational Site, Overland Park

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02281370 - Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects | Biotech Hunter | Biotech Hunter